DGAP-News: Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome
Newron Pharmaceut.
WKN: A0LF18 / Name: Newron Pharmaceut. / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /
8,49 €
-1,05 %
![DGAP-News: Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
DGAP-News: Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome
DGAP-News: Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome
| Unlocking Potential: Discover the transformative power of MetroEHS Pediatric Therapy. Our dedicated team of therapists specializes in ABA, speech, occupational, and feeding therapy, ensuring personalized care for your child's success. Embrace a brighter future with our comprehensive mental health services and convenient teletherapy options.
Neueste Beiträge
BennieRichards in Global Customer Engagement Review from Braze Finds Marketers are Prioritizing Increased Investments in Customer Retention, Braze Inc.